Tagged with “18qLOH”

MSI in Stage II Colon Cancer: Chemotherapy or Not?

Some of the most interesting data presented at ASCO was the data on MSI and 18qLOH in a European clinical trial.

Last year at ASCO, Dr. Daniel Sargent presented new data that patients with stage II disease with microsatellite instability do not only not benefit from 5-FU, but they may be harmed, and it was recommended to test for MSI in all stage II colon cancer patients and in the presence of MSI-high not to give 5-FU. For stage III colon cancer that was not the case.

This year, the PETACC-3 clinical trial was analyzed for MSI and did not show the same the same findings. It seems that chemotherapy does not harm these patients, and they may benefit. Continue reading…

Posted by Heinz-Josef Lenz, MD on June 8th, 2009
Posted in: From the Desk of Dr. Lenz | 6 Comments »
Tags: 18qLOH, ASCO 2009, MSI, personalized medicine, Understanding Genetics

Search C3

Free Patient Webinar

Stage II Colon Cancer: Chemo or Not? Find Your Solution
Monday, September 20, 2010
8:00 PM - 9:00 PM EDT

Stage II colon cancer patients face tough decisions about whether the possible benefits of chemotherapy outweigh its risks and challenges. This webinar will explore the answers with you.

Follow C3

Join us on Facebook

Watch us on YouTube

Register to receive our free e-newsletter

Get monthly updates on colorectal cancer treatment options, research news and advocacy opportunities. We promise to not bombard you with email - just enough to keep you informed on how to fight colorectal cancer.